Flurandrenolone and Occlusion in PsoriasisProlonged Topical Treatment
LAWRENCE FRANK, MD;
KARL STEINER, MD;
BENJAMIN BENDER, MD;
MARVIN WINSTON, MD
Arch Dermatol. 1964;89(3):404-410.
Abstract
| |
Twenty-two patients with psoriasis were treated with topically applied flurandrenolone cream and occlusion for extensive periods extending four weeks beyond the time when all lesions had disappeared. Biopsies were taken from apparently uninvolved skin and from a plaque of psoriasis prior to treatment, and then weekly thereafter from the psoriasis sites. Histologic and histochemical stains of the skin sections were done.
Results of the study show that complete resolution of the abnormal histologic and histochemical features of psoriasis does not occur. Even as late as four weeks after complete clinical clearance the sulfhydryl, disulfide, and ribonucleic acid changes are still apparent in the area of the previous gross psoriatic lesion. Clinically uninvolved skin also shows some evidence of abnormality in patients with psoriasis.
The clinical relapse rate in patients treated with topical flurandrenolone and occlusion for four weeks beyond clinical clearance was 54% in a six-month period of observation. It was felt that prolonged treatment reduced the relapse rate and increased the remission time.
Author Affiliations
BROOKLYN, NY
The Division of Dermatology, Department of Medicine, State University of New York, Downstate Medical Center, and the Dermatology Service, Kings County Hospital.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Flurandrenolone (Cordran) Tape and Carbohydrate Metabolizing Enzymes: Use in the Epidermis of People With Psoriasis
Halprin et al.
Arch Dermatol 1969;100:336-341.
ABSTRACT
Histopathology and Histochemistry of Psoriasis: I. The Active Lesion and Clinically Normal Skin
Gordon and Johnson
Arch Dermatol 1967;95:402-407.
ABSTRACT
|
